Initial Statement of Beneficial Ownership (3)
October 01 2021 - 4:11PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Shizuru Judith Anne |
2. Date of Event Requiring Statement (MM/DD/YYYY)
9/24/2021
|
3. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc. [JSPR]
|
|
(Last)
(First)
(Middle)
2200 BRIDGE PKWY SUITE #102 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Street)
REDWOOD CITY, CA 94065
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Voting Common Stock | 1129512 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (right to buy) | 2/26/2021 | 5/31/2030 | Common Stock | 146170 | $0.71 | D | |
| Explanation of Responses: |
| (1) | Includes 305,909 shares of restricted stock that are subject to vesting, of which 1/26th shall vest on October 20, 2021 and each month thereafter through and including November 20, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Remarks:
Exhibit 24 - Power of Attorney |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Shizuru Judith Anne
2200 BRIDGE PKWY SUITE #102
REDWOOD CITY, CA 94065 | X |
|
|
|
Signatures
|
| By: /s/ Jeet Mahal, as Attorney-in-Fact | | 10/1/2021 |
| **Signature of Reporting Person | Date |
Jasper Therapeutics (NASDAQ:JSPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jasper Therapeutics (NASDAQ:JSPR)
Historical Stock Chart
From Apr 2023 to Apr 2024
